# INTERNATIONAL STANDARD

ISO 21676

First edition 2018-10

Water quality — Determination of the dissolved fraction of selected active pharmaceutical ingredients, transformation products and other organic substances in water and treated waste water — Method using high performance liquid chromatography and mass spectrometric detection (HPLC-MS/MS or -HRMS) after direct injection

Qualité de l'eau — Détermination de la fraction dissoute des ingrédients pharmaceutiques actifs sélectionnés, des produits de la transformation et d'autres substances organiques dans l'eau et dans l'eau résiduaire — Méthode par chromatographie en phase liquide à haute performance et détection par spectrométrie de masse (CLHP-MS/MS ou -HRSM) après l'injection directe





© ISO 2018

Jementation, no partamical, includir requested fr All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office CP 401 • Ch. de Blandonnet 8 CH-1214 Vernier, Geneva Phone: +41 22 749 01 11 Fax: +41 22 749 09 47 Email: copyright@iso.org Website: www.iso.org

Published in Switzerland

Con	Contents					
Fore	vord		iv			
Intro	ductio	n	v			
1	Scop	е	1			
2	Norn	native references	4			
3	Term	s and definitions	4			
4		iple				
5		ferences				
U	5.1	During sample preparation	4			
	5.2	During high performance liquid chromatography and mass spectrometry				
6		Reagents				
	6.1 6.2	General Preparation of solutions				
7		ratus				
7						
8	_	oling				
9	<b>Proc</b> 9.1	edure General	8 8			
	9.2	Sample preparation				
	9.3	High performance liquid chromatography (HPLC)	9			
	9.4	Detection	9			
		9.4.1 General 9.4.2 Tandem mass spectrometry (MS/MS)				
		9.4.2 Tandem mass spectrometry (MS/MS)	10 10			
	9.5	Blank value measurements	10			
10	Calibration					
	10.1	General	10			
	10.2	Calibration with external standard				
	10.3	Calibration with internal standard				
11		llation of recovery General				
	11.1	Calculation of analyte recovery using samples				
	11.3	Recovery of internal standards	14			
12	Evalu	ation	14			
	12.1	Verification of individual substances	14			
	12.2	Calculation of the individual results using calibration with an external standard				
	12.3	Calculation of the individual results using calibration with an internal standard				
13	Expr	ession of results	16			
14		report				
		formative) <b>Performance data</b>				
Anne	<b>x B</b> (inf	formative) Examples of recovery	22			
Anne	<b>x</b> C (inf	Formative) Examples of HPLC columns and chromatograms	24			
Anne	<b>x D</b> (in	formative) Examples of detection	30			
Anne	<b>x E</b> (inf	Formative) Examples of extension of the method	33			
Bibli	ograph	y	34			

### **Foreword**

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see <a href="www.iso.org/directives">www.iso.org/directives</a>).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see <a href="https://www.iso.org/patents">www.iso.org/patents</a>).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see <a href="https://www.iso.org/iso/foreword.html">www.iso.org/iso/foreword.html</a>.

This document was prepared by Technical Committee ISO/TC 147, *Water quality*, Subcommittee SC 2, *Physical, chemical and biochemical methods*.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at <a href="https://www.iso.org/members.html">www.iso.org/members.html</a>.

# Introduction

Pharmaceutical ingredients are essential for human and animal health. Through application or improper disposal, active pharmaceutical ingredients enter the water cycle unchanged or transformed. This can happen via municipal waste water, treated at treatment plants. There, some active pharmaceutical ingredients and transformation products cannot be removed completely from the waste water by conventional treatment techniques. Active pharmaceutical ingredients and their transformation products also travel through sludge to the soil and subsequently enter water bodies via leachate, depending on the nature of the ground and the active ingredients. Active pharmaceutical ingredients and their transformation products are therefore found in treated waste water, as well as in surface action d fraction. and ground water. This document specifies a liquid chromatography method with mass spectrometric detection for the determination of selected active pharmaceutical ingredients and their transformation products in the dissolved fraction.

This document is a previous general ded by tills

Water quality — Determination of the dissolved fraction of selected active pharmaceutical ingredients, transformation products and other organic substances in water and treated waste water — Method using high performance liquid chromatography and mass spectrometric detection (HPLC-MS/MS or -HRMS) after direct injection

WARNING — Persons using this document should be familiar with normal laboratory practice. This document does not purport to address all of the safety problems, if any, associated with its use. It is the responsibility of the user to establish appropriate safety and health practices.

IMPORTANT — It is absolutely essential that tests conducted in accordance with this document be carried out by suitably qualified staff.

## 1 Scope

This document specifies a method for the determination of the dissolved fraction of selected active pharmaceutical ingredients and transformation products, as well as other organic substances (see <u>Table 1</u>) in drinking water, ground water, surface water and treated waste water.

The lower application range of this method can vary depending on the sensitivity of the equipment used and the matrix of the sample. For most compounds to which this document applies, the range is  $\geq 0.025 \,\mu\text{g/l}$  for drinking water, ground water and surface water, and  $\geq 0.050 \,\mu\text{g/l}$  for treated waste water.

The method can be used to determine further organic substances or in other types of water (e.g. process water) provided that accuracy has been tested and verified for each case, and that storage conditions of both samples and reference solutions have been validated. Table 1 shows the substances for which a determination was tested in accordance with the method. Table E.1 provides examples of the determination of other organic substances.

Table 1 — Substances for which a determination was tested in accordance with this method

Common name Chemical name (IUPAC <sup>2</sup> )	Molecular formula	Molar mass	CAS-RNb
	Y X	g/mol	
4-Acetylaminoantipyrine	C. all aNaOa	245 20	02.15.0
N-(2,3-Dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl)acetamide	C <sub>13</sub> H <sub>15</sub> N <sub>3</sub> O <sub>2</sub>	245,28	83-15-8
N4-Acetyl sulfamethoxazole	CHN-O.C	205.22	21312-10-7
N-{4-[(5-Methyl-1,2-oxazol-3-yl)sulfamoyl]phenyl}-acetamide	C <sub>12</sub> H <sub>13</sub> N <sub>3</sub> O <sub>4</sub> S	295,32	21312-10-/
Diatrizoic acid (amidotricoic acid)	CHINO	(12.01	117-96-4
3,5-Bis(acetamido)-2,4,6-triiodobenzoic acid $C_{11}H_9I_3N_2O_4$		613,91	117-90-4
Atenolol			
(RS)-2-[4-[2-Hydroxy-3-(1-methylethylamino) propoxy]phenyl] ethanamide	C <sub>14</sub> H <sub>22</sub> N <sub>2</sub> O <sub>3</sub>	266,34	29122-68-7
a IUPAC: International Union of Pure and Applied Chemistry.			
b CAS-RN: Chemical Abstracts System Registration Number.			

 Table 1 (continued)

Common name Chemical name (IUPAC <sup>a</sup> )	Molecular formula	Molar mass	CAS-RNb
		g/mol	
Bezafibrate			
2-{4-[2-(4-Chlorbenzamido)ethyl]phenoxyl}-2-methylpropanoic acid	C <sub>19</sub> H <sub>20</sub> ClNO <sub>4</sub>	361,80	41859-67-0
Bisoprolol			
(RS)-1-[4-(2-lsopropoxyethoxymethyl)phenoxy]-3-isopropylamino-2-propanol	C <sub>18</sub> H <sub>31</sub> NO <sub>4</sub>	325,45	66722-44-9
Carbamazepine	C <sub>15</sub> H <sub>12</sub> N <sub>2</sub> O	236,27	298-46-4
5H-Dibenzo[b,f]azepine-5-carbamide	CISHIZNZO	230,27	270-40-4
Clarithromycin			
(2R,3R,4S,5R,8R,9S,10S,11R,12R,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-5-ethyl-3,4-dihydroxy-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-oxan-2-yl]oxy-12-methoxy-2,4,8,10,12,14-hexamethyl-6-oxacyclotetradecane-1,7-dione	C <sub>38</sub> H <sub>69</sub> NO <sub>13</sub>	747,95	81103-11-9
Clofibric acid	C II ClO	244.70	002.00.7
2-(4-Chlorophenoxy)-2-methylpropanoic acid	C <sub>10</sub> H <sub>11</sub> ClO <sub>3</sub>	214,70	882-09-7
Dehydrato-Erythromycin (anhydro-erythromycin)			
(2R,3R,4S,5S,8R,9S,10S,11R,12R)-11-{[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-5-ethyl-3-hydroxy-9-[(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy]-2,4,8,10,12,14-hexamethyl-6,15,16-trioxatricyclo[10.2.1.1{1,4}]hexadecane-7-one	C <sub>37</sub> H <sub>65</sub> NO <sub>12</sub>	715,91	23893-13-2
Diazepam			
(RS)-7-Chlor-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-on	C <sub>16</sub> H <sub>13</sub> ClN <sub>2</sub> O	284,74	439-14-5
Diclofenac	$C_{14}H_{11}Cl_2NO_2$	296,15	15307-86-5
2-[2-[(2,6-Dichlorphenyl)amino]phenyl]acetic acid	C <sub>14</sub> H <sub>11</sub> C <sub>12</sub> NO <sub>2</sub>	290,15	15507-00-5
10,11-Dihydro-10,11-dihydroxy carbamazepine			
(5S,6S)-5,6-Dihydroxy-5,6-dihydrobenzo[b][1]benzazepie- 11-carboxamide	C <sub>15</sub> H <sub>14</sub> N <sub>2</sub> O <sub>3</sub>	270,29	58955-93-4
Erythromycin		5	
6-(4-Dimethylamino-3-hydroxy-6-methyl-oxan-2-yl)oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-oxan-2-yl)-oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione	C <sub>37</sub> H <sub>67</sub> NO <sub>13</sub>	733,93	114-07-8
4-Formylaminoantipyrine		6	
N-(2,3-Dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl) formamide	C <sub>12</sub> H <sub>13</sub> N <sub>3</sub> O <sub>2</sub>	231,25	1672-58-8
Gemfibrozil	C <sub>15</sub> H <sub>22</sub> O <sub>3</sub>	250,34	25812-30-0
5-(2,5-Chlorophenoxy)-2,2-methylpropanoic acid	015112203	230,37	23012-30-0
Ibuprofen	C <sub>13</sub> H <sub>18</sub> O <sub>2</sub>	206,28	15687-27-1
(RS)-2-[4-(2-Methylpropyl)phenyl]propanoic acid	013111802	200,20	13007-27-1
a IUPAC: International Union of Pure and Applied Chemistry.			
b CAS-RN: Chemical Abstracts System Registration Number.			

 Table 1 (continued)

Common name Chemical name (IUPAC <sup>a</sup> )	Molecular formula	Molar mass	CAS-RNb
<u> </u>		g/mol	
Iomeprol (±)-N,N'-Bis-(2,3-dihydroxypropyl)-5-[(2-hydroxy-acetyl) methylamino]-2,4,6-triiodo isophthalamide	C <sub>17</sub> H <sub>22</sub> I <sub>3</sub> N <sub>3</sub> O <sub>8</sub>	777,09	78649-41-9
Iopamidol			
(S)-N,N'-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxypropanoyl)amino]-2,4,6-triiodobenzene-1,3-dicarbamide	C <sub>17</sub> H <sub>22</sub> I <sub>3</sub> N <sub>3</sub> O <sub>3</sub>	777,08	60166-93-0
Iopromide			
(±)-N,N'-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-N-methylisophthalamide	C <sub>18</sub> H <sub>24</sub> I <sub>3</sub> N <sub>3</sub> O <sub>8</sub>	791,12	73334-07-3
Metoprolol			
(RS)-1-(Isopropylamino)-3-[4-(2-methoxyethyl) phenoxy] propan-2-ol	C <sub>15</sub> H <sub>25</sub> NO <sub>3</sub>	267,36	37350-58-6
Naproxen	C <sub>14</sub> H <sub>14</sub> O <sub>3</sub>	230,26	22204-53-1
(S)-2-(6-Methoxy-2-naphthyl)propanoic acid	014111403	230,20	22201 33 1
Oxazepam			
(RS)-7-Chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-on	C <sub>15</sub> H <sub>11</sub> ClN <sub>2</sub> O <sub>2</sub>	286,71	604-75-1
Phenazone	$C_{11}H_{12}N_2O$	188,23	60-80-0
1,5-Dimethyl-2-phenyl-2,3-dihydro-1H-pyrazol-3-on	GIIIIZIVZO	100,20	
Primidone	$C_{12}H_{14}N_2O_2$	218,25	125-33-7
5-Ethyl-5-phenylhexahydropyrimidin-4,6-dione	01211411202	210,20	120 00 7
Propyphenazone		222.24	.= =
1,5-Dimethyl-4-(1-methylethyl)-2-phenyl-1,2-dihydro-3H-pyrazol-3-one	C <sub>14</sub> H <sub>18</sub> N <sub>2</sub> O	230,31	479-92-5
Roxithromycin	0		
(3R,4S,5S,6R,7R,9R,11S,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl] oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-10-(2,4,7-trioxa-1-azaoctan-1-ylidene)-1-oxacyclotetradecane-2-one	C <sub>41</sub> H <sub>76</sub> N <sub>2</sub> O <sub>15</sub>	837,05	80214-83-1
Sotalol	(0)		
(RS)-4'-(1-Hydroxy-2-isopropylaminoethyl) methanesulfonanilide	C <sub>12</sub> H <sub>20</sub> N <sub>2</sub> O <sub>3</sub> S	272,36	3930-20-9
Sulfamethoxazole	C <sub>10</sub> H <sub>11</sub> N <sub>3</sub> O <sub>3</sub> S	253,28	723-46-6
4-Amino-N-(5-methyl-1,2-oxazol-3-yl)benzene-sulfonamide	CIUIIIIN3O35	233,20	723-40-0
Temazepam			
(RS)-7-Chloro-3-hydroxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one	C <sub>16</sub> H <sub>13</sub> ClN <sub>2</sub> O <sub>2</sub>	300,74	846-50-4
Trimethoprim	C <sub>14</sub> H <sub>18</sub> N <sub>4</sub> O <sub>3</sub>	290,32	738-70-5
2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine	014111811403	270,32	730-70-3
a IUPAC: International Union of Pure and Applied Chemistry.			
b CAS-RN: Chemical Abstracts System Registration Number.			

#### 2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 1042, Laboratory glassware — One-mark volumetric flasks

ISO 3696, Water for analytical laboratory use — Specification and test methods

ISO 4796-2, Laboratory glassware — Bottles — Part 2: Conical neck bottles

ISO 5667-4, Water quality — Sampling — Part 4: Guidance on sampling from lakes, natural and man-made

ISO 5667-5, Water quality — Sampling — Part 5: Guidance on sampling of drinking water from treatment works and piped distribution systems

ISO 5667-6, Water quality — Sampling — Part 6: Guidance on sampling of rivers and streams

ISO 5667-10, Water quality — Sampling — Part 10: Guidance on sampling of waste waters

ISO 5667-11, Water quality — Sampling — Part 11: Guidance on sampling of groundwaters

ISO 8466-1, Water quality — Calibration and evaluation of analytical methods and estimation of performance characteristics — Part 1: Statistical evaluation of the linear calibration function

### 3 Terms and definitions

No terms and definitions are listed in this document.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <a href="https://www.iso.org/obp">https://www.iso.org/obp</a>
- IEC Electropedia: available at <a href="http://www.electropedia.org/">http://www.electropedia.org/</a>

#### 4 Principle

The water sample is injected directly into the analysis system. The identification and quantitative determination is performed using high performance liquid chromatography coupled with mass spectrometric detection (HPLC-MS/MS, HPLC-HRMS).

#### 5 Interferences

#### 5.1 During sample preparation

Loss of analytes can occur during filtration of the sample as a result of sorption.

#### 5.2 During high performance liquid chromatography and mass spectrometry

Peak tailing, peak fronting and/or wide peaks are indications of a malfunctioning of HPLC and/or interferences occurring during chromatography. However, some compounds tend to show more signal tailing than others depending on the chromatographic conditions.

Interferences from accompanying substances (matrix) can occur in both positive and negative ionization modes depending on the measured compound (e.g. diclofenac in negative ESI mode).

Accompanying substances (matrix) can affect the ionization of the target substances (e.g. ion suppression or signal enhancement). This can result in underestimation or overestimation of concentration during